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Summary Up to now, we have performed scintigraphy with 201-thallium chloride (201-TlCl)
and 99m-Tc-hexakis-2-methoxy-isobutyl-isonitrile (99m-Tc-MIBI) for malignant tumors and
lymphoscintigraphy with 99m-Tc-rhenium-colloid (99m-Tc-Re) and 99m-Tc-human-serum-albu-
min-diethylene-triamine-penta-acetic-acid (99m-Tc-HSA-D) for lymph node metastasis. In this
article, we re-evaluated scintigraphic images retrospectively with a hope that the results might
be a clue, even if it is small, for dentists to try to improve the accuracy of diagnosis of malignant
tumors. From scintigraphy, we obtained the tumor retention index as a factor to estimate the
uptake of radioactive agents in tumor cells. Moreover, we estimated transport proteins of Na+/
K+-ATPase and permeability-glycoprotein (P-gp) expressed on the cell membrane that might
regulate the kinetic condition of radioactive agents. Among the tumor retention index, the
transport protein and the histopathologic finding of tumors, there were relatively well correla-
tions. The tumor retention index showed a difference clearly between malignant tumor and
benign tumor. The transport protein revealed a distinct expression in accordance with the
malignancy of tumor, and the uptake clearly depended upon the expression of transport protein.
Moreover, the lymph node metastasis was detected well by lymphoscintigraphy with 99m-Tc-Re
and 99m-Tc-HSA-D.
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Up to now, not a few radioactive agents have been introduced
for the purpose of diagnosing malignant tumors of the head
and neck, for example 67-Ga (gallium), 201-Tl (thallium),
99m-Tc (technetium), 198-Au (aurum), 131-I (iodine) and so
forth. However, these radioactive agents are now not popu-
larly used as before in routine examinations, because 18-F-
fluoro-deoxy-glucose positron emission tomography (FDG-
PET) is taking places of these radioactive agents. FDG-PET
is a very superior method for malignant tumors [1]. At the
time when FDG-PET has been introduced, we almost believed
that most malignant tumors could be detected precisely and
qualitatively with this method. However, this our expectation
unfortunately ended with a fragile dream. This is not any all-
purpose method. Even FDG-PET has some weak points. For
example, FDG-PET is not able to distinguish malignant tumors
from inflammatory lesions [2]. This radioactive agent shows
almost the same accumulation in both malignant tumors and
inflammatory lesions depending on its high sensitivity and
affinity both to tumors and inflammatory tissues. This weak
point is also an eternal, essential problem among usual tumor
scintigraphies for a long time. Many researchers have tried to
resolve this problem for a long time, but this is left unre-
solved. Against this problem, we also did in spite of a small
ability. We focused our eyes on transport proteins of radio-
active agents as one of means of solving this problem. We
performed evaluations concerning several subjects, for
example an expression of transport proteins on cell mem-
brane and a relation of transport proteins with accumulation.
Among the results of our evaluations, we searched to pick up
some factors that seemed to be helpful and useful for
diagnosing malignant tumors, and we tried to find out a
possibility of qualitative diagnosis of malignant tumors of
the head and neck using the factors [3—8]. In our scintigraphy
for tumors, we usually employed 201-thallium chloride (201-TlCl) and 99m-Tc-hexakis-2-methoxy-isobutyl-isonitrile
(99m-Tc-MIBI) as radioactive agents. We selected a couple
of factors that control and closely relate with the uptake of
these radioactive agents. We evaluated the expression of
Na+/K+-ATPase and permeability-glycoprotein (P-gp) on the
tumor cell membrane and the role of them as transport
proteins in relation with both accumulation and washout
of radioactive agents in tumor cells.
In this article, we re-evaluated retrospectively our results
of tumor scintigraphy that we carried out until now. More-
over, we also re-evaluated lymphoscintigraphy with 99m-Tc-
rhenium-colloid (99m-Tc-Re) and 99m-Tc-human-serum-
albumin-diethylene-triamine-pentaacetic-acid (99m-Tc-
HSA-D) [9—11]. With this thing and that, most data used in
this article were quoted from some of our previous reports on
journals [3—11] and modified to some extent.
Scintigraphy
Scintigraphy for tumors
Clinical evaluation of scintigraphy with 201-Tl
201-Tl was first used to evaluate the viability of the myo-
cardium. After a while, this agent was introduced for the
examination of malignant tumors of the head and neck
[12,13]. In this section, we evaluated the usefulness of
201-Tl for malignant tumors of the head and neck.
(Methods and materials of scintigraphy with 201-Tl). We
used 85 patients with a malignant tumor of the head and
neck (squamous cell carcinoma) and 10 patients with a benign
tumor (7 with pleomorphic adenoma and 3 with Warthin’s
tumor).
Intravenous injection of 74MBq of 201-Tl was performed.
An early dynamic scan (for 5 min immediately after injec-
tion), a delayed dynamic scan and a spot scan (at 2.5 h after
Figure 1 Two regions of interest (ROI) on a frame image
covered the tumor area (A) and the symmetrical region (B:
control region).
A clue for interpreting kinetics of scintigraphic agents 133injection) were carried out using a gamma camera. From the
dynamic scan, 2-s scans were obtained continuously. A single
2-s scan constituted a frame data. Two regions of interest
(ROI) on each frame covering both tumor and control areas
were used to estimate the uptake of 201-Tl (Fig. 1). Early and
delayed retention indexes were calculated from the results
of each dynamic scan. The early retention index was the ratio
of count of tumor to count of control in the early dynamic
scan. The delayed retention index was the ratio of count of
tumor to count of control in the delayed dynamic scan. FromFigure 2 Two curves showed radioactive count after injection
in the tumor and control areas. In the dynamic scintigraphy, the
early retention index was A/a and the delayed retention index
was B/b. The tumor retention index was (delayed retention
index)/(early retention index).these two indexes, the tumor retention index was calculated;
the ratio of the delayed retention index to the early retention
index (Fig. 2). We used this tumor retention index for the
evaluation of scintigraphy. The tumor retention index was
compared with the histopathologic type and tissue differ-
entiation.
(Results: tumor retention index of 201-Tl, histopathologic
type and tissue differentiation). Tumor retention indexes
varied widely ranging from 0.76 to 1.46 in patients. In the
histopathologic type, the tumor retention indexes ranged
from 0.76 to 0.93 (average was 0.82) in the benign group, and
0.78—1.46 (1.04) in the malignant group, respectively. In the
tissue differentiation, tumor retention indexes ranged from
0.78 to 1.24 (average was 1.03) in the well group, from 0.91
to 1.42 (1.09) in the moderate group, and from 1.05 to 1.46
(1.24) in the poor group, respectively. We classified these
tumor retention indexes into three groups: decreased
(<0.9), unchanged (0.9—1.1), and increased (>1.1). The
increased tumor retention index means that the washout
of 201-Tl from tumor is delayed or the washout function is
lost. On the other hand, the decreased tumor retention index
indicates that the washout of 201-Tl is fast. As for histo-
pathologic type, 80% of patients in the benign group belonged
to the decreased tumor retention index group and no patient
showed the increased. On the other hand, 28% and 67% of
patients in the malignant group were included in the
increased and unchanged groups. Only 5% of patients indi-
cated the decreased. As for the tissue differentiation, 86% of
patients in the poor group were included in the increased
group and no patient showed the decreased. On the other
hand, only 13% of patients in the well group belonged to the
increased group (Table 1). These results showed that 201-Tl
once taken up in malignant tumors had a tendency to remain.
Accumulation of 201-Tl and Na+/K+-ATPase expression
It was reported that the expression of Na+/K+-ATPase on cell
membrane was one of the most important factors concerning
the accumulation mechanism of 201-Tl in malignant tumors
[14]. However, the role of Na+/K+-ATPase on the uptake
mechanism of 201-Tl is not clearly understood, and there
are few reports on tumors of the head and neck. In this
section, we evaluated the role of Na+/K+-ATPase expression
on 201-Tl scintigraphy of malignant tumors of the head and
neck.
(Methods and materials of immunohistochemistry for Na+/
K+-ATPase expression). Sixty-five patients with malignant
tumor of the head and neck (squamous cell carcinoma)
and 22 patients with benign tumor were used.
Immunohistochemical staining was performed with tumor
samples. Briefly, sections of tumors were treated with sodium
citrate buffer, heated for the antigen retrieval, and then
treated hydrogen peroxide for 10 min to block endogenous
peroxidase activity. Sections were incubated with the pri-
mary and secondary antibody. After incubation, the sections
were washed with Tris buffer saline, reacted with avidin-
biotinylated-peroxidase complex, and stained with diamino-
bendizine [15]. Na+/K+-ATPase expression was graded into
score 0 (stained under 5%), score 1 (from 5 to 49%), or score 2
(over 50%) [16] with reference to the negative and positive
Table 1 Tumor retention index of 201-Tl, histopathologic type and tissue differentiation.
Tumor retention index Histopathologic type Tissue differentiation
Benign Malignant Well Moderate Poor
10 patients 85 53 patients 25 7
Decreased (<0.9) 80% 5 8% 0 0
Unchanged (0.9—1.1) 20 67 79 56 14
Increased (>1.1) 0 28 13 44 86
Table 2 Na+/K+-ATPase expression, histopathologic finding and tumor retention index.
Na+/K+-ATPase Histopathologic finding Scintigraphy
Benign Malignant Tumor retention index
Well Moderate Poor Decreased Unchanged Increased
22 patients 32 27 6 24 24 17
Score 0 32% 44% 0 16.7 41% 4 12
Score 1 59 40.5 56 16.7 45 58 35
Score 2 9 15.5 44 66.6 14 38 53
Table 3 Tumor retention index of 99m-Tc-MIBI and tissue
differentiation.
Tumor retention index Tissue differentiation
Well Moderate Poor
7 patients 8 4
Slightly
decreased (>0.9)
71% 12.5 0
Intermediately
decreased (0.9—0.8)
29 50 50
Severely
decreased (<0.8)
0 37.5 50
% decrease from early to
delayed (average)
9% 17.8 21
134 T. Sato et al.controls. We compared Na+/K+-ATPase expression with the
tumor retention index, histopathologic findings in malignant
tumors of the head and neck.
(Results: Na+/K+-ATPase expression, histopathologic finding
and tumor retention index). As for the Na+/K+-ATPase
expression and histopathologic finding, patients of the benign
group showed score 0 (32%), score 1 (59%) and score 2 (9%). In
the malignant group, scores 0, 1 and 2 were shown in 44%,
40.5% and 15.5% in the well group, respectively. Patients of
the moderate group showed score 1 (56%) and score 2 (44%).
In patients of the poor group, scores 0, 1 and 2 were shown in
16.7%, 16.7% and 66.6%, respectively. As for the Na+/K+-
ATPase expression and tumor retention index, patients of
the decreased group showed scores 0, 1, and 2 in 41%, 45%
and 14%, respectively. Patients of the unchanged group
revealed score 0 (4%), score 1 (58%) and score 2 (38%),
respectively. In patients of the increased group, scores 0,
1 and 2 were observed in 12%, 35% and 53%, respectively
(Table 2). The frequency of score 2 was elevated according as
the tumor retention index became large. These results indi-
cated that Na+/K+-ATPase expression was typical in malignant
tumors and played the role of uptake of 201-Tl.
Clinical evaluation of scintigraphy with 99m-Tc-MIBI
This scintigraphic agent has been widely used to evaluate the
viability of the myocardium, and the accumulation of this
agent in malignant tumors has been also reported [17]. In this
section, we evaluated the usefulness of 99m-Tc-MIBI scinti-
graphy for the diagnosis of malignant tumor of the head and
neck.
(Methods and materials of scintigraphy with 99m-Tc-
MIBI). Nineteen patients with squamous cell carcinoma of
the head and neck were used. The method of scintigraphy
was almost the same as that of 201-Tl. Scintigraphy was
performed with an intravenous injection of 600MBq of99m-Tc-MIBI [18]. The tumor retention index was compared
with the tissue differentiation.
(Results: tumor retention index of 99m-Tc-MIBI and tissue
differentiation). Retention indexes ranged from 1.1 to 3.1 in
the early dynamic scan, and averages were 1.03 (well group),
1.8 (moderate) and 1.65 (poor). In the delayed dynamic scan,
retention indexes ranged from 1.0 to 2.9, and averages were
1.1 (well group), 1.48 (moderate) and 1.27 (poor). From
these retention indexes, tumor retention indexes were cal-
culated. Tumor retention indexes ranged from 0.70 to 1.0,
and averages were 0.91 (well group), 0.93 (moderate) and
0.79 (poor), respectively. Then, we classified grades of tumor
retention indexes into >0.9 (slightly decreased), 0.9—0.8
(intermediately decreased) and >0.8 (severely decreased).
Most of tumor retention indexes were under 1.0. We could
find a decreasing tendency of tumor retention indexes from
the early dynamic scan to delayed dynamic scan in malignant
tumors of the head and neck. All patients in the well group
Table 5 Diagnostic reliability of 201-Tl and 99m-Tc-MIBI.
201-Tl 99m-Tc-MIBI
True positive 77% 68
False positive 1 0
False negative 16 32
True negative 5 0
Sensitivity 82.9% 68.4
Specificity 80.1 —
Accuracy 82.7 68.4
Table 4 P-gp expression, tissue differentiation and tumor retention index.
P-gp expression Tissue differentiation (71 patients) Tumor retention index (19)
Well Moderate Poor >0.9
(Slightly)
0.9—0.8
(Intermediately)
<0.8
(Severely)
39 patients 19 13 6 patients 8 5
Score 0 43% 11 0 67% 12.5 0
Score 1 49 63 69 33 50 60
Score 2 8 26 31 0 37.5 40
A clue for interpreting kinetics of scintigraphic agents 135belonged to the slightly or intermediately decreased indexes.
On the other hand, 50% of patients in the poor group showed
the severely decreased index. The ‘‘% decreases from the
early to delayed tumor retention index’’ were ranged from 0%
to 30%, and the average of poor group was 21% (Table 3).
These results revealed that 99m-Tc-MIBI once taken up in
malignant tumors was discharged from tumors gradually, and
this was opposite to 201-Tl.
Accumulation of 99m-Tc-MIBI and P-gp expression
99m-Tc-MIBI once accumulated is discharged gradually from
tumors. This washout of 99m-Tc-MIBI from tumors is recog-
nized with a tumor retention index, which is considered to
depend on the expression of P-gp in tumor cell membrane
[17,19]. Pg-p is observed on the cell membrane of both
normal and tumor cells, and the expression is more distinct
in malignant tumor cells [7]. However, there are few reports
concerning the role of P-gp on Tc-99m-MIBI scintigraphy in
malignant tumor of the head and neck. In this section, we
evaluated immunohistochemically the level and role of P-gp
in malignant tumors.
(Methods and materials of immunohistochemistry for P-gp
expression). One group of 19 patients underwent both 99m-
Tc-MIBI scintigraphy and an immunohistochemical examina-
tion. Moreover, another group of 71 patients underwent an
immunohistochemical examination of P-gp expression.
Samples of malignant tumor were treated in citrate buffer
to retrieve the antibody activity. They were incubated with
H2O2, horse serum and a primary monoclonal antibody of JSB-
1. They were incubated with secondary antibody solution,
diaminobenzidine, H2O2, and peroxidase substrate solution.
Finally, the nuclei were counter-stained with hematoxylin. In
addition to these samples, we used three other tissue sec-
tions for the control of negative, a moderately positive and a
severely positive stains [19]. We classified grades of staining
of P-gp expression into score 0 (less than 5% of tumor cells),
score 1 (5—50%) and score 2 (over 50%) [20]. We compared P-
gp expression with the tissue differentiation and the tumor
retention index in malignant tumors of the head and neck.
(Results: P-gp expression, tissue differentiation and tumor
retention index). With respect to the P-gp expression and
tissue differentiation in 71 patients, 43% and 49% of patients
in the well group showed score 0 and 1. On the other hand,
most patients in the poor group showed score 1 and score 2.
No patient showed score 0. As for the P-gp expression and
tumor retention index in 19 patients, 67% of patients in the
slightly decreased group showed score 0, and no patientshowed score 2. On the other had, 40% of patients in the
severely decreased group showed score 2, and no patient
showed score 0 (Table 4). These results indicated that P-gp
expression was distinct in patients of low differentiation
group and showed a well correlation with the discharge of
99m-Tc-MIBI.
Comparison of 201-Tl with 99m-Tc-MIBI
99m-Tc-MIBI and 201-Tl had each different uptake mechan-
ism. 99m-Tc-MIBI accumulated distinctly in malignant tumors
in the early phase, but the accumulation became less intense
in the late phase. 201-Tl also accumulated in malignant
tumors in the early phase, but the accumulation in the
delayed phase of malignant tumors did not show any distinct
decrease. In this section, we compared and evaluated the
usefulness of 201-Tl and 99m-Tc-MIBI for the diagnosis of
malignant tumors of the head and neck.
(Results: diagnostic reliability of 201-Tl with 99m-Tc-
MIBI). The true positive, false positive, false negative, true
negative, sensitivity, specificity and accuracy of the two
scintigraphic agents are shown (Table 5). The sensitivity,
specificity and accuracy of 201-Tl scintigraphy were 82.9%,
80.1% and 82.7%, respectively. On the other hand, the sensi-
tivity and accuracy were 68.4% and 68.4% in 99m-Tc-MIBI
scintigraphy. Thus, 201-Tl is a little superior to 99m-Tc-MIBI
as an agent for malignant tumors of the head and neck.
Scintigraphy for lymph nodes
(lymphoscintigraphy)
99m-Tc-Re had been used once as agents for lymphoscinti-
graphy to detect metastatic lymph nodes. 99m-Tc-Re was
composed of colloid of small particles (2—15 nm) [21,22] and
a good radioactive agent for lymphoscintigraphy. Unfortu-
Figure 3 Regions of interest (ROI) of cervical lymph nodes of
dynamic lymphoscintigraphy. They were the right and left super-
ior levels of internal jugular nodes (ROI numbers 1 and 2), the mid
internal jugular nodes (3 and 4) and the inferior internal jugular
nodes (5 and 6).
136 T. Sato et al.nately we cannot use this now in Japan because of legal
problems. We had an opportunity before to use this as a part
of clinical research of this agent. Injected 99m-Tc-Re was
taken into small lymphatic vessels and this uptake chiefly
depended on the pore size of the small lymphatic vessels. On
the other hand, 99m-Tc-HSA-D consisted of dextran [23].
Generally, dextran at molecular weight of over 50,000 was
taken into small lymphatic vessels [24]. The molecular
weight of 99m-Tc-HSA-D was over 50,000, so this agent easily
moved into small lymphatic vessels. Between 99m-Tc-Re and
99m-Tc-HSA-D, there was a difference in their mechanisms of
uptake. Criterion for a metastasis of lymph nodes was based
on the fact that normal lymph nodes could take 99m-Tc-Re or
99m-Tc-HSA-D, but metastatic lymph nodes decreased the
uptake of them or could not take them. We performed two
kinds of lymphoscintigraphy with them: a dynamic and a
static lymphoscintigraphy.Figure 4 Function curves of dynamic lymphoscintigraphy.
These curves indicated the change in flow of the radioactive
agent along the internal jugular chains. Curve numbers corre-
sponded to ROI numbers of cervical lymph nodes respectively.
Function curves showed various findings about changes in lym-
phatic system.Lymphoscintigraphy with 99m-Tc-Re
We performed lymphoscintigraphy for finding out and diag-
nosing of metastatic lymph nodes from malignant tumors of
the head and neck. Lymphoscintigraphy showed various
images. Metastasis of lymph node usually caused a change
of the flow rate in lymphatic vessels and a change of uptake of
radioactive agent in lymph nodes. Therefore, lymphoscinti-
graphic images could show the change of lymph node function
on the basis of the pathological change, and the change might
be useful as a criterion for evaluation of lymph node metas-
tasis. 99m-Tc-Re had been used in lymphoscintigraphy of
internal jugular chains for a long time, but there were few
clinical reports on this agent. In this section, we examined
and evaluated the changes of internal jugular nodes due to
metastases from malignant tumors of the head and neck by
lymphoscintigraphy with 99m-Tc-Re.
(Methods and materials of lymphoscintigraphy with 99m-Tc-
Re). Dynamic lymphoscintigraphy with Tc-99m-Re was eval-
uated on 17 patients with squamous cell carcinomas. Static
lymphoscintigraphy was evaluated on 32 patients.
Dynamic lymphoscintigraphy was carried out immediately
after the subcutaneous injection of 99m-Tc-Re (37MBq each)
in both areas behind the ears simultaneously [9—11]. Twenty-
second-scans were obtained continuously for 20 min. A 20 s-
scan was recorded as a frame datum, and 60 frames were
obtained. On each frame, six regions of interest covering
both sides of internal jugular chains were used for evaluation
of lymph node function (Fig. 3). Obtained frame data were
used to make ‘‘Function curves’’ (Fig. 4). Function curves
showed a lot of information about the lymphatic system.
Furthermore, static images of lymphoscintigraphy were
obtained 3 h after the injection.
(Result-1: pathologic examination and dynamic lymphoscin-
tigraphy with 99m-Tc-Re). Ten of 17 patients were proved to
be metastasis pathologically and they all showed a positive
lymphoscintigraphic image (true positive). 7 of 17 patients
were proved to be normal pathologically. 4 patients showed a
positive lymphoscintigraphic image (false positive) and 3
patients revealed a negative image (true negative). The
true-positive, false-positive, false-negative and true-nega-
tive were found in 71%, 29%, 0% and 100%. Then, the sensi-Table 6 Pathologic examination and dynamic lymphoscin-
tigraphy with 99m-Tc-Re.
Pathologic examination Dynamic
lymphoscihoscintigraphy
Metastasis 10 patients Positive 10 patients
Negative 0
Normal 7 patients Positive 4 patients
Negative 3
True positive 71%
False positive 29
False negative 0
True negative 100
Sensitivity 100%
Specificity 43
Accuracy 76
Table 7 Pathologic examination and static lymphoscinti-
graphy with 99m-Tc-Re.
Pathologic examination Static
lymphoscintigraphy
Metastasis 24 patients Positive 24 patients
Negative 0
Normal 8 patients Positive 5 patients
Negative 3
True positive 83%
False positive 17
False negative 0
True negative 100
Sensitivity 100%
Specificity 38
Accuracy 84
Table 8 Pathologic examination and dynamic lymphoscin-
tigraphy with 99m-Tc-HSA-D.
Pathologic examination Dynamic
lymphoscintigraphy
Metastasis 9 patients Positive 9 patients
Negative 0
Normal 5 patients Positive 5 patients
Negative 0
True positive 64%
False positive 36
False negative —
True negative —
Sensitivity 100%
Specificity 0
Accuracy 64
Table 10 Diagnostic reliability of 99m-Tc-Re and 99m-Tc-
HSA-D.
Lymphoscintigraphy Statistical data
Sensitivity Specificity Accuracy
99m-Tc-Re Dynamic 100% 43 76
Static 100 38 84
99m-Tc-HSA-D Dynamic 100% 0 64
Static 100 20 71
A clue for interpreting kinetics of scintigraphic agents 137tivity, specificity and accuracy were 100%, 43% and 76% (Table
6).
(Result-2: pathologic examination and static lymphoscinti-
graphy with 99m-Tc-Re). Twenty-four of 32 patients were
proved to be metastasis pathologically and they all showed aTable 9 Pathologic examination and static lymphoscinti-
graphy with 99m-Tc-HSA-D.
Pathologic examination Static
lymphoscintigraphy
Metastasis 9 patients Positive 9 patients
Negative 0
Normal 5 patients Positive 4 patients
Negative 1
True positive 69%
False positive 31
False negative 0
True negative 100
Sensitivity 100%
Specificity 20
Accuracy 71positive lymphoscintigraphic image (true positive). 8 of 32
patients were proved to be normal pathologically. 5 patients
showed a positive lymphoscintigraphic image (false positive)
and 3 patients revealed a negative image (true negative).
The true-positive, false-positive, false-negative and true-
negative were found in 83%, 17%, 0% and 100%. Then, the
sensitivity, specificity and accuracy were 100%, 38% and 84%
(Table 7).
Lymphoscintigraphy with 99m-Tc-HSA-D
Lymphoscintigraphy with 99m-Tc-HSA-D might be somewhat
different from 99m-Tc-Re in findings depending on the dif-
ferent component from that of 99m-Tc-Re [24].
(Methods and materials of lymphoscintigraphy with 99m-Tc-
HAS-D). Dynamic and static lymphoscintigraphy with 99m-
Tc-HSA-D were performed in 14 patients with squamous cell
carcinoma of the head and neck.
We injected 74MBq of 99m-Tc-HSA-D subcutaneously in
both areas behind ears. Dynamic and static lymphoscintigra-
phy were carried out. The criteria of metastasis were almost
the same as those of 99m-Tc-Re.
(Result-1: pathologic examination and dynamic lymphoscin-
tigraphy with 99m-Tc-HSA-D). Nine of 14 patients were
proved to be metastasis pathologically and they all showed
a positive lymphoscintigraphic image (true positive). 5 of 14
patients were proved to be normal pathologically. They all
showed a positive lymphoscintigraphic image (false positive).
The true-positive and false-positive were found in 64% and
36%. Then, the sensitivity and accuracy were 100% and 64%
(Table 8).
(Result-2: pathologic examination and static lymphoscinti-
graphy with 99m-Tc-HSA-D). All patients proved to be metas-
tasis pathologically showed a positive lymphoscintigraphic
image (true positive). 4 of 5 patients proved to be normal
pathologically showed a positive lymphoscintigraphic image
(false positive) and 1 patient revealed a negative image (true
negative). The true-positive, false-positive, false-negative
and true-negative were found in 69%, 31%, 0% and 100%.
Then, the sensitivity, specificity and accuracy were 100%, 20%
and 71% (Table 9).
Comparison of 99m-Tc-Re with 99m-Tc-HSA-D
99m-Tc-Re was composed of uniform particles of a suitable
size for the pores. 99m-Tc-Re flew through small lymphatic
vessels, then reached lymph nodes. On the other hand, 99m-
Tc-HSA-D did not consist of any colloidal particles [10,11],
138 T. Sato et al.therefore the mechanism of uptake of this radioactive agent
in lymph nodes was very different from that of 99m-Tc-Re,
and because of this their lymphoscintigraphic patterns were
assumed to be different in some degree.
(Results: diagnostic reliability of 99m-Tc-Re and 99m-Tc-
HSA-D). The sensitivity, specificity and accuracy of lymphos-
cintigraphy with 99m-Tc-Re and 99m-Tc-HSA-D were shown in
Table 10. In comparison of 99m-Tc-Re with 99m-Tc-HSA-D,
99m-Tc-Re showed a high accuracy both in the dynamic and
static lymphoscintigraphy, and was estimated to be superior
to 99m-Tc-HSA-D as an agent for lymphoscintigraphy. This
might depended on the component of each agent: 99m-Tc-Re
was consisted of colloid and 99m-Tc-HSA-D was dextran.
Discussion
We made re-evaluation of some of our previous reports [3—
11] on scintigraphy for malignant tumors and lymph node
metastasis. There were some clues to find a solution to
problems in scintigraphy. The results in this article indicated
a possible hint to make a qualitative diagnosis of malignant
tumors or to differentiate malignant tumors from inflamma-
tory lesions. For example, tumor retention indexes showed
different tendencies between malignant lesions and benign
lesions including inflammatory changes, or the level of trans-
port proteins on cell membrane have a possible clue to reveal
grades of tissue differentiation of tumors like tumor markers.
Scintigraphy for tumors with 201-Tl and 99m-Tc-
MIBI
Both 201-Tl and 99m-Tc-MIBI are now rarely used for diagnosis
of malignant tumors of the head and neck [8] because FDG-
PET has been widely introduced for the same purpose [1].
However, 201-Tl and 99m-Tc-MIBI have some advantages to
FDG-PET, for example, transport proteins (Na+/K+-ATPase for
201-Tl and P-gp for 99m-Tc-MIBI) were helpful for qualitative
diagnosis and have a possibility to become factors like tumor
markers. In addition, 201-Tl and 99m-Tc-MIBI are not so
expensive. In this article, we re-evaluated retrospectively
the usefulness of 201-Tl and 99m-Tc-MIBI for a diagnosis of
tumors of the head and neck. We could obtain important
information from dynamic scintigraphy. In the early phase,
both 201-Tl and 99m-Tc-MIBI accumulated well in viable
tumor cells [12,18], although they have physical differences.
Tl+ has physical effects similar to K+ and is taken up actively
because it has an ion radius similar to K+, and malignant
tumors need a large amount of K+ [25,26]. On the other hand,
99m-Tc-MIBI accumulated in tumor cells by plasma mem-
brane potentials [6]. With respect to the accumulation
mechanism in the delayed phase, we performed some eva-
luations and obtained some useful results. 99m-Tc-MIBI first
reached tumor cells through the tumor vascular system and
was taken into tumor cells by plasma membrane potentials.
Next, the accumulated 99m-Tc-MIBI was discharged from
tumor cells by P-gp expressed on the cell membrane which
was well known as a responsible protein in the multi-drug
resistance [27]. On the other hand, 201-Tl was first brought to
tumor cells like 99m-Tc-MIBI, and the accumulation in tumor
cells was increased by the active transportation with Na+/K+-ATPase expressed on the cell membrane [28]. In our inves-
tigation, the accumulation of 201-Tl in the delayed phase
correlated well with Na+/K+-ATPase [5]. As for the relation-
ship with the tumor retention index, the tissue differentia-
tion and tumor retention index showed an evident
correlation. This suggested that tumor retention indexes
correlated with transport proteins. Tomura et al. [29]
reported a tendency that the tumor retention index of
malignant tumors decreased in 99m-Tc-MIBI scintigraphy.
They reported an about 30% decrease. On the other hand,
Tonami et al. [30] reported a decreased tumor retention
index of 4.6—6% in benign tumors, and demonstrated an
increase of more than 20% in malignant tumors in 201-Tl
scintigraphy. Thus, the tumor retention index decreased with
99m-Tc-MIBI and increased with 201-Tl when tumors were
malignant [31]. In this article, we showed the usefulness of
99m-Tc-MIBI and 201-Tl, especially we showed that the tumor
retention index showed a good correlation with the grade of
tumor malignancy, and that the accumulation chiefly
depended on transport proteins of Na+/K+-ATPase and P-gp
[5,32,33].
Scintigraphy for lymph nodes with 99m-Tc-Re and
99m-Tc-HSA-D
Lymphoscintigraphy is now performed for detecting sentinel
lymph nodes of malignant tumors [34]. However, we had
performed this method for detecting and diagnosing meta-
static lymph nodes from malignant tumors of the head and
neck [9—11]. For the purpose of those, we used two kinds of
agents: 99m-Tc-Re and 99m-Tc-HSA-D. Between 99m-Tc-Re
and 99m-Tc-HSA-D, there is a difference in the mechanism of
uptake because these two agents are composed of different
components [9,23,24]. In this article, we re-evaluated retro-
spectively the usefulness of lymphoscintigraphy with 99m-Tc-
Re and 99m-Tc-HSA-D and compared the results each other.
We carried out two types of scintigraphies: a dynamic and
astatic lymphoscintigraphy. In dynamic lymphoscintigraphy,
both 99m-Tc-Re and 99m-Tc-HSA-D showed no false negative,
but showed false positive. This result might depend on the
fact that lymphatic drainages easily changed even if the
pathology of lymph nodes was benign or malignant, and
usually showed variable pattern. Sometime lymphatic drai-
nages change even in normal conditions. The accuracy of
diagnosis was 76% in 99m-Tc-Re and 64% in 99m-Tc-HSA-D
respectively, but their specificities were not high. In static
lymphoscintigraphy, the accuracy was 84% in 99m-Tc-Re and
71% 99m-Tc-HSA-D, but their specificities were as low as
those dynamic scintigraphy. The low specificities might
depend on the fact that lymph nodes might show changes
in advance to metastasis, for example inflammatory effects
from tumor tissues. Moreover, it might be a cause to the low
specificity that it was impossible to let all lymph nodes have
one to one correspondence to each other between lymphos-
cintigraphy and pathologic examination. In comparison of
99m-Tc-Re with 99m-Tc-HSA-D, 99m-Tc-Re showed a slightly
higher agreement with pathological findings than Tc-99m-
HSA-D. Unfortunately, it is difficult now to find out a single
lymph node metastasis or a micro metastasis. These results of
our evaluation of dynamic and static lymphoscintigraphy
might be a hint to solve problems.
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At the present time that 201-Tl, 99m-Tc-MIBI, 99m-Tc-Re
and 99m-Tc-HSA-D become not to be used popularly in
comparison with FDG-PET, we do not expect that our pre-
vious results are useful or helpful to the routine dental
practice directly. However, FDG-PET is recently found to
have a problem in diagnosis of malignant tumors, for exam-
ple FDG-PET accumulates both in malignant tumors and
inflammatory lesions. This is just the problem that we also
tried to resolve until now. Therefore, we hope that even a
small part of our results shown in this article could be a clue
or hint for dentists to try to find out a solution of problem, if
it is a very small help.
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